Breakthrough: New Injectable Therapy Could Prevent Heart Failure After Heart Attack

Scientists from Northwestern University and the University of California San Diego have developed a groundbreaking, potent injectable therapy that shows immense promise in protecting the heart from long-term damage following a heart attack, potentially preventing the progression to heart failure.

This innovative therapeutic approach utilizes specially designed protein-like polymers (PLPs) that act as artificial antibodies within heart tissue. These PLPs effectively “grab” and neutralize regulatory proteins, known as Keap1, which typically hinder the body’s natural healing processes. By freeing up protective proteins like Nrf2, the therapy allows them to combat stress and inflammation, crucial steps in preventing further cardiac damage.

Mechanism and Promising Results

Heart failure, often a devastating consequence of heart attacks, affects millions globally. When a heart attack occurs, damage from lack of oxygen and oxidative stress leads to inflammation and scarring, eventually weakening the heart. Current treatments focus on restoring blood flow but often fall short in preventing this long-term deterioration.

The research team specifically targeted the interaction between two proteins:

Nrf2: A protective protein that safeguards heart cells from stress and inflammation by activating healing genes.
Keap1: A regulatory protein that binds to Nrf2, preventing it from entering the cell’s nucleus to exert its protective effects.

The scientists engineered a PLP with multiple “arms” designed to strongly bind to Keap1, mimicking a part of the Nrf2 protein. This prevents Keap1 from inhibiting the natural Nrf2, allowing Nrf2 to enter the cell’s nucleus and activate protective genes.

After demonstrating success in cell cultures, the therapy was tested in a rat model of heart attack. A single, low-dose intravenous injection resulted in:

Decreased inflammation and cell death.
Improved cardiac function.
Increased growth of new blood vessels.
The therapy remained effective for up to five weeks post-injection.

Experts Weigh In

Dr. Nathan Gianneschi, a senior author of the study from Northwestern, highlighted the significance: “Our work introduces an entirely new type of therapy capable of addressing previously ‘undruggable’ targets within the cells. It offers a promising strategy to change the course of this devastating disease.”

Dr. Karen Christman, who co-led the study from UC San Diego, added: “The goal of this therapy is to intervene very soon after someone suffers a heart attack to keep them from ultimately going into heart failure.”

Commercialization and Future Directions

The study was published in the journal Advanced Materials. The revolutionary PLP platform is now being commercialized by Grove Biopharma, a Northwestern spin-out company that recently secured a $30 million Series A financing round.

Beyond heart disease, researchers believe this novel PLP platform represents a significant advancement in therapeutic development, offering a new tool to tackle challenging biological targets where traditional approaches have failed. Grove Biopharma is already exploring PLPs to target protein-protein interactions in various other diseases, with initial focus areas including cancer and neurodegenerative diseases. This could unlock therapeutic avenues for numerous conditions currently without effective treatments.